SurModics, Inc.
Eden Prairie, MN 55344
Share:
Surmodics Announces Successful First Patient Uses of Two Sublime™ Radial Access Platform Devices
Sublime™ Radial Access .014 RX PTA Dilatation Catheter, Sublime Radial Access Guide Sheath Deliver Outstanding Performance in Initial Physician Evaluations EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful first uses with patients for two...
Read More »
The Surmodics Sundance™ Sirolimus-Coated Balloon Catheter Earns FDA Breakthrough Device Status
Sundance™ Sirolimus-Coated Balloon will receive prioritization throughout the FDA submission and review process to provide patients and physicians timely access to medical devices EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States Food...
Read More »Surmodics Sublime™ Guide Sheath Receives FDA 510(k) Approval
Guide sheath is the first of Surmodics’ family of products designed for peripheral procedures accessed from the radial artery EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its...
Read More »12-Month Data from Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2018
Study met primary endpoint and all 12-month secondary safety endpoints including 100 percent freedom from CD-TLR or TVR Results demonstrated continued clinically significant improvement in ABI, walking distance, walking speed and stair-climbing scores at 12 months EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic...
Read More »
New MatrixGuard Diluents Reduce the Risk of False Positives
The MatrixGuard™ Diluents consistently balances maximum blocking activity of matrix interferences by simultaneously maintaining assay signal across multiple formats. The MatrixGuard™ enables manufacturer to produce assay components to increase performance and manufacturability of immunoassays. The product improves performance of assay by lowering backgrounds and increases signal generation...
Read More »
Surmodics Announces FDA Clearance of a New .018 Low-Profile PTA Balloon Dilation Catheter
Company received FDA 510(k) clearance Continued progress in R&D whole-product solutions pipeline EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its .018” Low-Profile percutaneous...
Read More »
Surmodics Announces Global Approvals of .014 Low-Profile PTA Balloon Dilation Catheter
The company received FDA 510(k) and CE Mark clearance EDEN PRAIRIE, Minn. - Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) and CE Mark clearance for its .014” low-profile percutaneous transluminal angioplasty (PTA) balloon dilation...
Read More »SurModics Expands Protein-Free Stabilizer Line with AP Option
AACC Annual Meeting and Clinical Lab Expo 2014 EDEN PRAIRIE, Minn.-- SurModics IVD, Inc., a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for in vitro diagnostic assay components, is introducing StabilZyme-® Protein-Free AP Stabilizer at the American Association for Clinical Chemistry meeting currently taking place in Chicago. “Protein interference is a frequent...
Read More »TMB Stop Solution is non-corrosive and non-hazardous.
BioFX-® Liquid Nova-Stop Solution provides non-corrosive, non-hazardous stop solution for TMB microwell substrates. While offering alternative to stop solutions that contain sulfuric acid or hydrochloric acid, product also exhibits minimal signal drift. ELISA assay kit manufacturers can include- solution in their products without needing to label and ship products as corrosive, and no labelling...
Read More »SurModics IVD Breakthrough Stabilizer Addresses Industry Challenge
EDEN PRAIRIE, Minn.- – SurModics IVD, Inc., a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for in vitro diagnostic assay components, is launching its new StabilZyme-® Protein-Free Stabilizer today at the American Association for Clinical Chemistry (AACC) meeting in Houston. “This newest addition to SurModics’ stabilization line is significant for assay...
Read More »
Surmodics Announces Successful First Patient Uses of Two Sublime™ Radial Access Platform Devices
Sublime™ Radial Access .014 RX PTA Dilatation Catheter, Sublime Radial Access Guide Sheath Deliver Outstanding Performance in Initial Physician Evaluations EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful first uses with patients for two...
Read More »Surmodics to Host Virtual Annual Meeting of Shareholders
Virtual Meeting on February 11 at 4 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Thursday, February 11, at 4:00 p.m. CT (5:00 p.m. ET), as a virtual meeting. Gary Maharaj, chief executive officer, and Sue Knight,...
Read More »Surmodics Names Nusrath Sultana, MD, as Vice President, Clinical Affairs
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Nusrath Sultana, MD, has joined Surmodics as Vice President, Clinical Affairs, effective February 3, 2020. “We are fortunate to have someone of Nusrath’s caliber joining the Surmodics team,” said Gary...
Read More »
The Surmodics Sundance™ Sirolimus-Coated Balloon Catheter Earns FDA Breakthrough Device Status
Sundance™ Sirolimus-Coated Balloon will receive prioritization throughout the FDA submission and review process to provide patients and physicians timely access to medical devices EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States Food...
Read More »Surmodics Completes Enrollment in Pivotal TRANSCEND Clinical Trial
Study designed to evaluate safety, efficacy of the company’s next-generation SurVeil™ drug-coated balloon Company Raises 2019 Revenue and EPS Guidance Eden Prairie, Minn.-- (Business Wire) -- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has completed enrollment in TRANSCEND, its pivotal...
Read More »Surmodics Sublime™ Guide Sheath Receives FDA 510(k) Approval
Guide sheath is the first of Surmodics’ family of products designed for peripheral procedures accessed from the radial artery EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its...
Read More »Surmodics Provides Update Regarding TRANSCEND Clinical Trial
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, has resumed patient enrollment into its TRANSCEND clinical trial and is nearly 75 percent of the way to its goal of 446 randomized patients. Patient enrollment in TRANSCEND, the pivotal clinical trial for the SurVeil™...
Read More »12-Month Data from Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2018
Study met primary endpoint and all 12-month secondary safety endpoints including 100 percent freedom from CD-TLR or TVR Results demonstrated continued clinically significant improvement in ABI, walking distance, walking speed and stair-climbing scores at 12 months EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic...
Read More »Surmodics Names Teri Sides as Chief Marketing Officer
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Teri Sides has joined Surmodics as Senior Vice President and Chief Marketing Officer, effective November 1, 2018. I am thrilled to welcome Teri to our internal team. Teri has been an important contributor to...
Read More »
New MatrixGuard Diluents Reduce the Risk of False Positives
The MatrixGuard™ Diluents consistently balances maximum blocking activity of matrix interferences by simultaneously maintaining assay signal across multiple formats. The MatrixGuard™ enables manufacturer to produce assay components to increase performance and manufacturability of immunoassays. The product improves performance of assay by lowering backgrounds and increases signal generation...
Read More »